Table 1 Characteristics of study patients
Age (years), median (range) | 60.0 (20.0–80.0) |
|---|---|
Sex (male/female) (%) | 245 (47.5)/ 271 (52.5) |
Body weight (kg), median (range) | 58.0 (36.35–107.6) |
BMI, median (range) | 22.7 (15.8–37.0) |
Prior treatment for HCV (no/yes) (%) | 359 (69.6)/ 157 (30.4) |
Initial dose of PEG-IFN (μg), median (range) | 80.0 (40.0–150.0) |
Initial dose of ribavirin (mg), median (range) | 600 (400–1000) |
Pretreatment HCV RNA levels (log10 IU/mL), median (range) | 6.1 (5.0–7.7) |
Platelet count (×103/μL) | 161 (43–352) |
Hemoglobin (g/dL) | 13.9 (9.7–17.9) |
Neutrophil count (/μL) | 2489 (578–7480) |
Alanine aminotransferase (IU/L) | 47 (10–485) |
LDL-cholesterol (mg/dL) | 99 (25–226) |
Total-cholesterol (mg/dL) | 171 (29–325) |
γ-glutamyl transpeptidase (IU/L) | 34.5 (7.0–579) |
Alfa fetoprotein (ng/mL) | 5.0 (0.8–584) |
Fibrosis score (F1/F2/F3/F4) (%) | 208(45.9)/139(30.7)/69(15.2)/37(8.2) |
Activity score (A1/A2/A3/A4) (%) | 258(56.1)/178(38.7)/24(5.2)/0(0) |
Genetic polymorphisms of rs8099917 (TT/GG or TG) (%) | 288 (72.7)/ 108(27.3) |
Amino acid at residue 70 of HCV core (arginine/glutamine or histidine) (%) | 242 (67.0)/ 119 (33.0) |
Amino acid sequence of ISDR (non-wild-type/wild-type) (%) | 110 (26.4)/ 306 (73.6) |